Cargando…
The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses
BACKGROUND: This year marks the twentieth anniversary of the approval by the US Food and Drug Administration of interleukin-2 (IL2) for use in cancer therapy, initially for renal cell carcinoma and later for melanoma. IL2 therapy for cancer has stood the test of time, with continued widespread use i...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421468/ https://www.ncbi.nlm.nih.gov/pubmed/22904643 http://dx.doi.org/10.2147/CMAR.S33979 |